迈克生物
(300463)
| 流通市值：45.72亿 | | | 总市值：56.23亿 |
| 流通股本：4.92亿 | | | 总股本：6.05亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,034,014,365.87 | 475,257,129.69 | 2,170,468,429.26 | 1,607,884,075.22 |
| 营业总成本 | 1,008,213,833.27 | 471,357,185.17 | 2,158,960,092.16 | 1,517,055,095.03 |
| 其他经营收益 | | | | |
| 营业利润 | 15,948,166.67 | 10,073,424.52 | -60,759,870.83 | 61,984,402.16 |
| 利润总额 | 17,061,801.44 | 8,404,477.88 | -99,537,391.47 | 34,501,768.56 |
| 净利润 | 29,611,877.51 | 6,602,934.01 | -41,494,108.29 | 43,024,083.77 |
| 每股收益 | | | | |
| 其他综合收益 | -1,264,807.02 | 19,257.97 | -15,250,936.63 | -15,058,213.16 |
| 综合收益总额 | 28,347,070.49 | 6,622,191.98 | -56,745,044.92 | 27,965,870.61 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 3,123,767,020.78 | 3,199,033,996.16 | 3,228,033,606.98 | 3,412,441,963.83 |
| 非流动资产: | | | | |
| 非流动资产合计 | 4,694,865,181.78 | 4,791,685,562.23 | 4,766,541,926.1 | 4,576,543,741.21 |
| 资产总计 | 7,818,632,202.56 | 7,990,719,558.39 | 7,994,575,533.08 | 7,988,985,705.04 |
| 流动负债: | | | | |
| 流动负债合计 | 782,366,652.21 | 1,011,850,410.34 | 1,053,376,455.01 | 980,670,442.62 |
| 非流动负债: | | | | |
| 非流动负债合计 | 702,252,175.48 | 666,580,651.69 | 635,532,773.69 | 628,930,234.34 |
| 负债合计 | 1,484,618,827.69 | 1,678,431,062.03 | 1,688,909,228.7 | 1,609,600,676.96 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 6,308,626,045.1 | 6,284,639,216.31 | 6,275,633,895.19 | 6,326,115,358.6 |
| 股东权益合计 | 6,334,013,374.87 | 6,312,288,496.36 | 6,305,666,304.38 | 6,379,385,028.08 |
| 负债和股东权益合计 | 7,818,632,202.56 | 7,990,719,558.39 | 7,994,575,533.08 | 7,988,985,705.04 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,260,587,850.37 | 637,571,828.44 | 2,826,351,272.14 | 1,991,748,511.64 |
| 经营活动现金流出小计 | 1,001,200,357.9 | 489,374,155.87 | 2,224,018,770.95 | 1,681,369,859.76 |
| 经营活动产生的现金流量净额 | 259,387,492.47 | 148,197,672.57 | 602,332,501.19 | 310,378,651.88 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 139,170,973.07 | 8,053,804.09 | 203,071,388.18 | 152,912,142.27 |
| 投资活动现金流出小计 | 276,466,057.26 | 125,270,799.55 | 925,656,453.34 | 637,394,934.85 |
| 投资活动产生的现金流量净额 | -137,295,084.19 | -117,216,995.46 | -722,585,065.16 | -484,482,792.58 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 347,013,957.27 | 227,704,235.03 | 817,636,648.58 | 830,309,635.83 |
| 筹资活动现金流出小计 | 357,342,950.46 | 200,750,449.59 | 675,245,451.72 | 628,546,211.12 |
| 筹资活动产生的现金流量净额 | -10,328,993.19 | 26,953,785.44 | 142,391,196.86 | 201,763,424.71 |
| 汇率变动对现金及现金等价物的影响 | -9,855,540.66 | -4,716,771.61 | -3,830,668.28 | -1,717,889.33 |
| 现金及现金等价物净增加额 | 101,907,874.43 | 53,217,690.94 | 18,307,964.61 | 25,941,394.68 |
| 期末现金及现金等价物余额 | 761,319,579.01 | 712,629,395.52 | 659,411,704.58 | 667,045,134.65 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 101,907,874.43 | - | 18,307,964.61 | - |